Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?

Andres F. Carrion, Fabrizio Fabrizi, Paul Martin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hepatitis C virus infection adversely affects outcomes in patients with chronic kidney disease undergoing maintenance dialysis. Pegylated interferon and ribavirin, the standard-of-care treatment in patients with intact renal function, is associated with severe side effects, toxicity, and high dropout rates in this population. Ribavirin has an important role in maintaining antiviral response following completion of therapy and increases sustained viral response (SVR) rates. However, the use of ribavirin in dialysis patients has been limited by the high frequency of severe hemolytic anemia and is currently reserved for study protocols and highly selected candidates treated at experienced centers. Encouraging data from small trials have shown a significant increase in SVR rates with the use of different dosing regimens of ribavirin in addition to interferon-based therapy and aggressive erythroid-stimulating agent support in dialysis patients. Use of ribavirin in selected dialysis patients, particularly renal transplant candidates, by experienced clinicians is appropriate.

Original languageEnglish
Pages (from-to)272-274
Number of pages3
JournalSeminars in Dialysis
Volume24
Issue number3
DOIs
StatePublished - May 1 2011

Fingerprint

Ribavirin
Hepatitis C
Dialysis
Interferons
Kidney
Hemolytic Anemia
Virus Diseases
Standard of Care
Chronic Renal Insufficiency
Hepacivirus
Antiviral Agents
Therapeutics
Maintenance
Transplants
Population

ASJC Scopus subject areas

  • Nephrology

Cite this

Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients? / Carrion, Andres F.; Fabrizi, Fabrizio; Martin, Paul.

In: Seminars in Dialysis, Vol. 24, No. 3, 01.05.2011, p. 272-274.

Research output: Contribution to journalArticle

Carrion, Andres F. ; Fabrizi, Fabrizio ; Martin, Paul. / Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?. In: Seminars in Dialysis. 2011 ; Vol. 24, No. 3. pp. 272-274.
@article{819ffd43028141bcb7e8382424e3cf50,
title = "Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?",
abstract = "Hepatitis C virus infection adversely affects outcomes in patients with chronic kidney disease undergoing maintenance dialysis. Pegylated interferon and ribavirin, the standard-of-care treatment in patients with intact renal function, is associated with severe side effects, toxicity, and high dropout rates in this population. Ribavirin has an important role in maintaining antiviral response following completion of therapy and increases sustained viral response (SVR) rates. However, the use of ribavirin in dialysis patients has been limited by the high frequency of severe hemolytic anemia and is currently reserved for study protocols and highly selected candidates treated at experienced centers. Encouraging data from small trials have shown a significant increase in SVR rates with the use of different dosing regimens of ribavirin in addition to interferon-based therapy and aggressive erythroid-stimulating agent support in dialysis patients. Use of ribavirin in selected dialysis patients, particularly renal transplant candidates, by experienced clinicians is appropriate.",
author = "Carrion, {Andres F.} and Fabrizio Fabrizi and Paul Martin",
year = "2011",
month = "5",
day = "1",
doi = "10.1111/j.1525-139X.2011.00851.x",
language = "English",
volume = "24",
pages = "272--274",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Should Ribavirin Be Used to Treat Hepatitis C in Dialysis Patients?

AU - Carrion, Andres F.

AU - Fabrizi, Fabrizio

AU - Martin, Paul

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Hepatitis C virus infection adversely affects outcomes in patients with chronic kidney disease undergoing maintenance dialysis. Pegylated interferon and ribavirin, the standard-of-care treatment in patients with intact renal function, is associated with severe side effects, toxicity, and high dropout rates in this population. Ribavirin has an important role in maintaining antiviral response following completion of therapy and increases sustained viral response (SVR) rates. However, the use of ribavirin in dialysis patients has been limited by the high frequency of severe hemolytic anemia and is currently reserved for study protocols and highly selected candidates treated at experienced centers. Encouraging data from small trials have shown a significant increase in SVR rates with the use of different dosing regimens of ribavirin in addition to interferon-based therapy and aggressive erythroid-stimulating agent support in dialysis patients. Use of ribavirin in selected dialysis patients, particularly renal transplant candidates, by experienced clinicians is appropriate.

AB - Hepatitis C virus infection adversely affects outcomes in patients with chronic kidney disease undergoing maintenance dialysis. Pegylated interferon and ribavirin, the standard-of-care treatment in patients with intact renal function, is associated with severe side effects, toxicity, and high dropout rates in this population. Ribavirin has an important role in maintaining antiviral response following completion of therapy and increases sustained viral response (SVR) rates. However, the use of ribavirin in dialysis patients has been limited by the high frequency of severe hemolytic anemia and is currently reserved for study protocols and highly selected candidates treated at experienced centers. Encouraging data from small trials have shown a significant increase in SVR rates with the use of different dosing regimens of ribavirin in addition to interferon-based therapy and aggressive erythroid-stimulating agent support in dialysis patients. Use of ribavirin in selected dialysis patients, particularly renal transplant candidates, by experienced clinicians is appropriate.

UR - http://www.scopus.com/inward/record.url?scp=79959358422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959358422&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2011.00851.x

DO - 10.1111/j.1525-139X.2011.00851.x

M3 - Article

VL - 24

SP - 272

EP - 274

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 3

ER -